This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Pharmacokinetics, Pharmacodynamics and Safety of D...
Clinical trial

Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment na�ve Patients

Read time: 1 mins
Last updated:30th Sep 2013
This study will explore the relationship of different DEB025 doses in combination with RBV to pharmacokinetic, pharmacodynamic (i.e. viral load reduction) and safety profiles in chronic hepatitis C GT 2 and 3 treatment na�ve patients.
Category Value
Study start date 2013-09-30

View full details